Skip to main content
SPTX logo

Seaport Therapeutics, Inc.

SPTXNASDAQHealthcareBiotechnology

$17.63Today:- (-)

As of Oct 15, 2026 close

Market cap
$621.21M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$14.85$28.38
Volume (live)
-
Avg. volume (3M)
271.00K

Seaport Therapeutics (SPTX) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Seaport Therapeutics had return on equity of -28.1%, debt-to-equity of 0.02 (up from 0.02), a current ratio of 17.46 (down from 27.82) and return on assets of -18.9%. A current ratio of 17.46 means current assets exceed current liabilities.

Seaport Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024
Period endingDec 2025Dec 2024
Valuation Ratios
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)-28.08%-
Return on Assets (ROA)-18.90%-
Return on Capital Employed (ROCE)-36.10%-17.20%
Leverage & Solvency Ratios
Debt/Equity0.020.02
Liquidity Ratios
Current Ratio17.4627.82
Quick Ratio17.1327.72
Efficiency Ratios
Yield & Distribution Ratios
Buyback Yield-151.76%-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Seaport Therapeutics Financial Ratios

What is Seaport Therapeutics's return on equity?

Seaport Therapeutics's return on equity (ROE) was -28.1% for fiscal 2025 (period ended Dec 31, 2025).

What is Seaport Therapeutics's debt-to-equity ratio?

Seaport Therapeutics's debt-to-equity ratio was 0.02 for fiscal 2025 (period ended Dec 31, 2025). It was 0.02 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition